摘要:
The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
摘要:
The present invention describes a novel cross-linker, a method for preparing one or more cross-linked biomolecules, biomolecular complexes of two or more biomolecules, a method for preparing cross-linked fragments from such cross-linked biomolecules and/or biomolecular complexes, a method for cleavage and reduction of such cross-linked biomolecules and/or biomolecular complexes, a method for identifying cross-links in such cross-linked biomolecules and/or biomolecular complexes, as well as a method for determining relative amounts of cross-links in a biomolecule or biomolecular complex in two or more samples.
摘要:
The invention relates to a compound represented by general formula (I) wherein Z represents N, O or S, and a represents a CH group, a nitrogen atom or an NL+ group wherein L represents a straight-chained or branched C1-C12 alkyl group. The invention also relates to a method for the preparation thereof and the use thereof as an antimitotic.
摘要:
A compound or its salt having the following formula (II) is used as an activator for PPAR δ:
[in which each of R 11 and R 13 is a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms and a halogen atom substituent, etc.; R 12 is a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms and a halogen atom substituent, etc.; each of R 14 and R 15 is a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, or an alkyl group having 1 to 8 carbon atoms and a halogen atom substituent; X 1 is CH or N; Z 1 is an oxygen atom or a sulfur atom; W 1 is an oxygen atom or CH 2 ; and q is an integer of 2 to 4].
摘要翻译:使用具有下式(II)的化合物或其盐作为PPAR'的活化剂:[其中R 11和R 13各自为氢原子,具有1至8个碳原子的烷基,具有 1〜8个碳原子的烷基,碳原子数1〜8的烷基和卤素原子取代基等。 R 12为氢原子,碳原子数1〜8的烷基,碳原子数1〜8的烷氧基,碳原子数1〜8的烷基和卤原子取代基等。 R 14和R 15各自为氢原子,碳原子数1〜8的烷基或碳原子数1〜8的烷基和卤素原子取代基。 X 1为CH或N; Z 1是氧原子或硫原子; W 1是氧原子或CH 2; q为2〜4的整数]。
摘要:
Compounds of formulae (VIII), (IX), (X), (XI), (XII) (XIII), (XIV) and (XV), in which the variables are as defined in the claims are described, as well as methods, pharmaceutical compositions and kits for treating or preventing amyloid-related disease.
摘要:
Selected sulfonic acids, their derivatives and pharmaceutical compositions containing such compounds are useful in inhibiting the chernotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCRI and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, the selected sulfonic acids and their derivativas are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
摘要:
Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine, in particular their use in the treatment of prostaglandin mediated diseases such as pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.